Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06247839 · ClinicalTrials.gov registry record · Phase 3
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder
A Phase 3 study of Major Depressive Disorder, sponsored by Sharmin Ghaznavi.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06247839 is a Phase 3 study of Major Depressive Disorder that is actively recruiting participants, run by Sharmin Ghaznavi. The registered enrollment target is 20 participants, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06247839, a Phase 3 study of Major Depressive Disorder, is actively recruiting participants, sponsored by Sharmin Ghaznavi.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This open-label functional Magnetic Resonance Imaging (fMRI) study will assess the effects of a single dose of psilocybin on rumination and the neural correlates of rumination in individuals with major depressive disorder.
Conditions Studied
Interventions
- DRUG Psilocybin
Study Locations (1)
Massachusetts
- Athinoula A. Martinos Center for Biomedical Imaging - Charlestown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-09-10 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06247839
The ClinicalTrials.gov registry entry for NCT06247839 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (95% lower). The listed sponsor is Sharmin Ghaznavi, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 1 intervention - of which Psilocybin is the first listed.
NCT06247839 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06247839 about?
NCT06247839 is a clinical study titled "The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder". This open-label functional Magnetic Resonance Imaging (fMRI) study will assess the effects of a single dose of psilocybin on rumination and the neural correlates of rumination in individuals with major depressive disorder.
What is the current status of trial NCT06247839?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 20 participants. The study started on 2024-09-10. Estimated completion is 2026-06-30.
What conditions does trial NCT06247839 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT06247839?
The interventions under investigation include: Psilocybin (DRUG).
Who is sponsoring clinical trial NCT06247839?
This trial is sponsored by Sharmin Ghaznavi, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06247839 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 3
-
Study to Assess the Safety and Effectiveness of NMRA-335140-501
RECRUITING · Phase 3
-
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 3
-
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"
RECRUITING · Phase 3
-
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 3
-
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.